Amgen sues Sanofi, Regeneron over PCSK9

Amgen Inc. (NASDAQ:AMGN) filed a lawsuit in the U.S. District Court for the District of Delaware alleging that alirocumab from Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) infringes three Amgen patents covering monoclonal antibodies against proprotein convertase subtilisin/kexin type 9 ( PCSK9).

Amgen is seeking an injunction to prevent Sanofi and Regeneron from manufacturing and selling alirocumab within the U.S. or from importing the human mAb targeting PCSK9 into the U.S. prior to the expiration of Amgen's patents, which have an estimated expiration date of 2029, according to the company's most recent 10K. Amgen also is seeking a ruling that alirocumab infringes its patents and wants monetary damages for any sales ahead of expiration of the patents. The suit also demands a jury trial. ...